2015 Annual Meeting | 2CO.003 - Clinical Research: Drug Development and Clinical Trials
| 01:00 PM - 01:10 PM |
Introduction
Wendy R. Galpern, MD, PhD, FAAN, Kwan-hong C. Min, MD, PhD |
|
| 01:10 PM - 01:40 PM |
Target Selection and Discovery Process
Peter Lansbury, PhD |
|
| 01:40 PM - 02:10 PM |
Early Stage Development: Decisions and Challenges
Alfred W. Sandrock, MD, PhD |
|
| 02:10 PM - 02:40 PM |
Late Stage Development: Decisions and Challenges
Ira Shoulson, MD |
|
| 02:40 PM - 02:55 PM |
Break
|
|
| 02:55 PM - 03:25 PM |
Clinical Trial Design Considerations
Christopher Coffey, PhD, FAAN |
|
| 03:25 PM - 03:55 PM |
Investigational New Drug Applications
Wilson W. Bryan, MD |
|
| 03:55 PM - 04:25 PM |
Discussion
|
|
| 04:25 PM - 04:55 PM |
Questions and Answers
|
|
| 04:55 PM - 05:00 PM |
Wrap Up and Summary
Wendy R. Galpern, MD, PhD, FAAN, Kwan-hong C. Min, MD, PhD |
| Wendy R. Galpern, MD, PhD, FAAN | No disclosure on file |
| Kwan-hong C. Min, MD, PhD | No disclosure on file |
| Ira Shoulson, MD | Dr. Shoulson has received research support from Vaccinex. |
| Wilson W. Bryan, MD | Dr. Bryan has received personal compensation in the range of $100,000-$499,999 for serving as a Director, Office of Tissues and Advanced Therapies with United States Food and Drug Administration (FDA). |
| Christopher Coffey, PhD, FAAN | Dr. Coffey has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. The institution of Dr. Coffey has received research support from NIH. The institution of Dr. Coffey has received research support from Michael J Fox Foundation. |
| Peter Lansbury, PhD | No disclosure on file |
| Alfred W. Sandrock, MD, PhD | No disclosure on file |